HIV PROTEASE INHIBITORS
Granted: July 11, 2019
Application Number:
20190210978
The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herin. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
MULTISPECIFIC ANTIBODIES THAT TARGET HIV GP120 AND CD3
Granted: December 27, 2018
Application Number:
20180371086
Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.
METHOD OF PURIFYING AN ANTIBODY
Granted: September 20, 2018
Application Number:
20180265543
The present disclosure relates generally to methods of producing, processing, or purifying antibodies. The present disclosure also relates to methods of producing, processing, or purifying a target antibody from cell cultures to remove host cell proteins.
METHOD FOR TREATING A PULMONARY HYPERTENSION CONDITION
Granted: May 18, 2017
Application Number:
20170136016
A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years
SOLID FORMS OF AN ASK1 INHIBITOR
Granted: September 29, 2016
Application Number:
20160280683
Crystalline forms of 5-(4-cyclopropyl-1H-imidazol-1-yl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.
Processes for preparing ASK1 inhibitors
Granted: August 25, 2016
Application Number:
20160244430
The present disclosure provides processes for the preparation of a compound of formula: which exhibits apoptosis signal-regulating kinase (“ASK1”) inhibitory activity and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis. The disclosure also provides compounds that are synthetic intermediates.
TANK-BINDING KINASE INHIBITOR COMPOUNDS
Granted: April 7, 2016
Application Number:
20160096827
Compounds having the following formula (I) and methods of their use and preparation are disclosed:
BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS
Granted: March 17, 2016
Application Number:
20160075695
This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R1, R1b, R2a, R2b, R3, R4a, R4b, and R5 are described herein.
MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS
Granted: March 10, 2016
Application Number:
20160067360
The present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.
TANK-BINDING KINASE INHIBITOR COMPOUNDS
Granted: December 3, 2015
Application Number:
20150344473
Compounds having the following formula (I) and methods of their use and preparation are disclosed:
SYNTHESIS OF AN ANTIVIRAL COMPOUND
Granted: June 25, 2015
Application Number:
20150175626
The present disclosure provides processes for the preparation of a compound of formula I: which is useful as an antiviral agent. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic intermediates to the compound of formula I.
CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND
Granted: June 25, 2015
Application Number:
20150175625
Crystalline forms of the anti-HCV compound (1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-9-ethyl-18,18-difluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of…
TABLETS FOR COMBINATION THERAPY
Granted: June 4, 2015
Application Number:
20150150810
The invention provides solid dose forms (e.g. tablets) comprising a compound of Formula I, a compound of Formula II, a compound of Formula III and a salt of Formula IV.
COMBINATION THERAPY FOR TREATING PULMONARY HYPERTENSION
Granted: May 7, 2015
Application Number:
20150125546
Method of treating and/or preventing pulmonary arterial hypertension comprising administering effective amounts of ambrisentan or a pharmaceutically acceptable salt thereof and riociguat or a pharmaceutically acceptable salt thereof.
NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION
Granted: April 23, 2015
Application Number:
20150111891
The invention provides compounds and salts thereof as d herein. The invention also provides pharmaceutical compositions comprising a compound disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection, treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds disclosed herein.
COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY
Granted: April 23, 2015
Application Number:
20150111856
The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (?)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants…
COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY
Granted: April 23, 2015
Application Number:
20150111855
The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (?)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants…
COMBINATION THERAPY COMPRISING TENOFOVIR ALAFENAMIDE HEMIFUMARATE AND COBICISTAT FOR USE IN THE TREATMENT OF VIRAL INFECTIONS
Granted: April 16, 2015
Application Number:
20150105350
The use of the hemifumarate form of {9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine} (tenofovir alafenamide hemifumarate) in combination with cobicistat is disclosed. In addition, the combination of tenofovir alafenamide hemifumarate, cobicistat, emtricitabine, and elvitegravir, and the combination of tenofovir alafenamide hemifumarate, cobicistat, emtricitabine, and darunavir, are disclosed.
ANTIVIRAL COMPOUNDS
Granted: March 19, 2015
Application Number:
20150080569
The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
PROCESS FOR PREPARING DRONEDARONE AND SALTS THEREOF
Granted: March 5, 2015
Application Number:
20150065734
The present disclosure relates to processes for preparing dronedarone or pharmaceutically acceptable salts thereof.
